Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Chi

Showing results (261-270 of 410) with videos related to

Pageof 41
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 14, 2023
Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN studyAxel S Merseburger, Neeraj Agarwal, Amitabha Bhaumik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2020
Genomic and Immunologic Characterization of INI1-Deficient Pediatric CancersSuzanne J Forrest, Alyaa Al-Ibraheemi, Duong Doan, et al.
Journal of Neuro-Oncology|April 14, 2017
Long-term neuropsychological follow-up of young children with medulloblastoma treated with sequential high-dose chemotherapy and irradiation sparing approachTaryn B Fay-McClymont, Danielle M Ploetz, Don Mabbott, et al.
Cancer Discovery|January 26, 2018
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate CancerMatti Annala, Gillian Vandekerkhove, Daniel Khalaf, et al.
The Lancet. Oncology|December 19, 2015
Classification of treatment-related mortality in children with cancer: a systematic assessmentSarah Alexander, Jason D Pole, Paul Gibson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2017
A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid TumorsBirgit Geoerger, Franck Bourdeaut, Steven G DuBois, et al.
European Urology Oncology|December 10, 2023
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate CancerEric J Small, Kim N Chi, Simon Chowdhury, et al.
Cancer Chemotherapy and Pharmacology|March 23, 2021
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)Fred Saad, Kim N Chi, Neal D Shore, et al.
The Journal of Urology|July 26, 2024
Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN TrialSoumyajit Roy, Yilun Sun, Kim N Chi, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 28, 2020
Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialistsSebastien J Hotte, Antonio Finelli, Kim N Chi, et al.
Pageof 41

Showing results (261-270 of 410) with videos related to

Sort By:
Pageof 41
European Journal of Cancer (Oxford, England : 1990)|September 14, 2023
Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN studyAxel S Merseburger, Neeraj Agarwal, Amitabha Bhaumik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2020
Genomic and Immunologic Characterization of INI1-Deficient Pediatric CancersSuzanne J Forrest, Alyaa Al-Ibraheemi, Duong Doan, et al.
Journal of Neuro-Oncology|April 14, 2017
Long-term neuropsychological follow-up of young children with medulloblastoma treated with sequential high-dose chemotherapy and irradiation sparing approachTaryn B Fay-McClymont, Danielle M Ploetz, Don Mabbott, et al.
Cancer Discovery|January 26, 2018
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate CancerMatti Annala, Gillian Vandekerkhove, Daniel Khalaf, et al.
The Lancet. Oncology|December 19, 2015
Classification of treatment-related mortality in children with cancer: a systematic assessmentSarah Alexander, Jason D Pole, Paul Gibson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2017
A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid TumorsBirgit Geoerger, Franck Bourdeaut, Steven G DuBois, et al.
European Urology Oncology|December 10, 2023
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate CancerEric J Small, Kim N Chi, Simon Chowdhury, et al.
Cancer Chemotherapy and Pharmacology|March 23, 2021
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)Fred Saad, Kim N Chi, Neal D Shore, et al.
The Journal of Urology|July 26, 2024
Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN TrialSoumyajit Roy, Yilun Sun, Kim N Chi, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 28, 2020
Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialistsSebastien J Hotte, Antonio Finelli, Kim N Chi, et al.
Pageof 41